The anticonvulsant fosphenytoin is safe and effective in quickly decreasing pain from sudden attacks of acute trigeminal ...

Various conditions may cause intercostal neuralgia. Neuropathic pain can occur when the somatosensory nerves become damaged or inflamed. It can have several different causes, though the treatment ...

"Treatment for mitochondrial diseases within reach." ScienceDaily. www.sciencedaily.com / releases / 2025 / 04 / 250409114701.htm (accessed April 22, 2025). Explore More ...

Prince Harry has claimed he was “singled out for inferior treatment” after he was stripped of his taxpayer-funded security protection in the UK. The Duke of Sussex, 40, arrived at London’s ...

The treatment will depend on the source of the pain. Guyuron B, Alessandri Bonetti M, Caretto AA. Comprehensive Criteria for Differential Diagnosis and a Surgical Management Algorithm for Occipital ...

Treatment relies on medication and may vary depending on ... and is usually located over one of the temples—which might be on the right side. Occipital neuralgia is a rare cause of secondary headaches ...

(Courtesy photo) Defense Health Agency officials are examining military treatment facilities across the military medical system, facility by facility, to determine their fate — which could ...

From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...

Fungal diseases are an increasing public health concern, with common infections – such as candida, which causes oral and vaginal thrush – growing increasingly resistant to treatment.

Peripheral nerve hydrodissection is a novel technique that can be applied in the treatment of neuropathic pain and musculoskeletal ... The patient underwent ultrasound-guided bilateral greater ...

Nine supervised drug injection sites have been successfully transitioned into Homelessness and Addiction Recovery Treatment (HART) Hubs across the province and will begin offering services on April 1, ...

Additionally, Vanda initiated a Phase III clinical study for Bysanti™ as a once-daily adjunctive treatment for major depressive disorder (MDD) in the fourth quarter of 2024. Results are expected ...